Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25590545 | 0.90 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL25024362 | 0.87 | CRBN (0.50) | CRBNDDB1IKZF3 | |
| SCHEMBL31312948 | 0.86 | DDB1 (0.55) | CRBNDDB1ACACB | |
| SCHEMBL25024363 | 0.86 | CRBN (0.49) | CRBNDDB1IKZF3 | |
| SCHEMBL31313237 | 0.84 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL30741711 | 0.84 | CRBN (0.53) | CRBNDDB1IKZF3 | |
| SCHEMBL31342588 | 0.83 | CRBN (0.47) | CRBNDDB1IKZF3 | |
| SCHEMBL31333353 | 0.82 | CRBN (0.45) | CRBNDDB1 | |
| SCHEMBL25846125 | 0.81 | CRBN (0.45) | CRBNDDB1IKZF3 | |
| SCHEMBL31312912 | 0.80 | CRBN (0.77) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | BEONE MEDICINES I GMBH (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024246838-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | CRBN 152/4885DDB1 607/4885ALDH1A1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.